THERAtRAME

Executive Summary

THERAtRAME is a Belgian biotechnology company pioneering first-in-class small molecule therapies targeting tRNA epitranscriptomics for cancer treatment, founded in 2017 and based in Liège. The company leverages novel insights into RNA modifications to develop oncology therapeutics, addressing a largely underexplored area of gene expression regulation. Although still in early stages with limited public details on its pipeline or funding, THERAtRAME's focus on translational control through tRNA modifications positions it at the forefront of epitranscriptomics-based drug discovery. The company's ability to advance its platform and secure investment will be critical for its growth and validation in a competitive landscape.

Upcoming Catalysts (preview)

• Q4 2026Release of preclinical proof-of-concept data for lead program60% success
• Q2 2026Series A financing round50% success
• Q3 2026Strategic research collaboration with academic or pharma partner40% success